

# Predictive test for chemotherapy response in resectable retrospective analysis

Lancet Oncology, The  
19, 629-638

DOI: [10.1016/s1470-2045\(18\)30108-6](https://doi.org/10.1016/s1470-2045(18)30108-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Precision medicine in the adjuvant treatment of gastric cancer. <i>Lancet Oncology</i> , The, 2018, 19, 583-584.	5.1	22
2	A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. <i>Annals of Oncology</i> , 2018, 29, 2356-2362.	0.6	32
3	Radiomic signature of <sup>18</sup> F fluorodeoxyglucose PET/CT for prediction of gastric cancer survival and chemotherapeutic benefits. <i>Theranostics</i> , 2018, 8, 5915-5928.	4.6	115
4	Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT. <i>Gastroenterology</i> , 2018, 155, 799-814.e13.	0.6	83
5	Immunomarker Support Vector Machine Classifier for Prediction of Gastric Cancer Survival and Adjuvant Chemotherapeutic Benefit. <i>Clinical Cancer Research</i> , 2018, 24, 5574-5584.	3.2	111
6	Modification of the TNM Staging System for Stage II/III Gastric Cancer Based on a Prognostic Single Patient Classifier Algorithm. <i>Journal of Gastric Cancer</i> , 2018, 18, 142.	0.9	12
7	Significance of Preoperative Systemic Immune Score for Stage I Gastric Cancer Patients. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-10.	0.7	6
8	Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2157-2166.	1.2	14
9	Dissection of gastric cancer heterogeneity for precision oncology. <i>Cancer Science</i> , 2019, 110, 3405-3414.	1.7	65
10	Gastric cancer: Translating novel concepts into clinical practice. <i>Cancer Treatment Reviews</i> , 2019, 79, 101889.	3.4	60
11	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3392-3400.	0.8	293
12	Clinical and molecular prognostic markers of survival after surgery for gastric cancer: tumor-node-metastasis staging system and beyond. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 59-59.	1.5	21
13	Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. <i>Yonsei Medical Journal</i> , 2019, 60, 132.	0.9	31
14	Blast from the past: Perioperative use of the Maruyama computer program for prediction of lymph node involvement in the surgical treatment of gastric cancer following neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1957-1963.	0.5	1
15	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1439-1450.	1.9	12
16	Comment on "To Treat, or Not to Treat, That is the Question Biomarker-guided Adjuvant Chemotherapy for Stage II and III Gastric Cancer". <i>Annals of Surgery</i> , 2019, 270, e40-e41.	2.1	6
17	Functional polymorphisms in circadian positive feedback loop genes predict postsurgical prognosis of gastric cancer. <i>Cancer Medicine</i> , 2019, 8, 1919-1929.	1.3	11
18	Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer. <i>PLoS ONE</i> , 2019, 14, e0214872.	1.1	19

#	ARTICLE	IF	CITATIONS
19	The predictive value of the preoperative C-reactive protein/albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data. <i>Gastric Cancer</i> , 2019, 22, 1016-1028.	2.7	59
20	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. <i>Yonsei Medical Journal</i> , 2019, 60, 235.	0.9	11
21	EPB41L5 Mediates TGF $\beta$ <sup>2</sup> -Induced Metastasis of Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3617-3629.	3.2	27
22	Clinical Implementation of Precision Medicine in Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2019, 19, 235.	0.9	16
23	PI3K/AKT/ $\beta$ -Catenin Signaling Regulates Vestigial-Like 1 Which Predicts Poor Prognosis and Enhances Malignant Phenotype in Gastric Cancer. <i>Cancers</i> , 2019, 11, 1923.	1.7	22
24	Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-10.	3.2	263
25	Nomogram for predicting gastric cancer recurrence using biomarker gene expression. <i>European Journal of Surgical Oncology</i> , 2020, 46, 195-201.	0.5	73
26	EphA2/YAP pathway drives gastric cancer growth and therapy resistance. <i>International Journal of Cancer</i> , 2020, 146, 1937-1949.	2.3	50
27	Prognostic significance of body mass index and prognostic nutritional index in stage II/III gastric cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 620-625.	0.5	43
28	Synthesis and application of magnetic-surfaced pseudo molecularly imprinted polymers for zearalenone pretreatment in cereal samples. <i>Food Chemistry</i> , 2020, 308, 125696.	4.2	42
29	Fucoidan suppresses the gastric cancer cell malignant phenotype and production of TGF $\beta$ <sup>1</sup> via CLEC-2. <i>Glycobiology</i> , 2020, 30, 301-311.	1.3	11
30	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. <i>Cancer Treatment Reviews</i> , 2020, 84, 101950.	3.4	19
31	Four transcription profile-based models identify novel prognostic signatures in oesophageal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 711-721.	1.6	10
32	Biomarkers for Precision Treatment in Gastric Cancer. <i>Visceral Medicine</i> , 2020, 36, 364-372.	0.5	14
33	Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study. <i>EBioMedicine</i> , 2020, 61, 103023.	2.7	9
34	Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer. <i>Annals of Surgery</i> , 2021, 274, e1153-e1161.	2.1	99
35	Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination. <i>Gut</i> , 2021, 70, 1823-1832.	6.1	38
36	Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32433-32442.	3.3	200

#	ARTICLE	IF	CITATIONS
37	Chemotherapy Use and Survival Among Young and Middle-Aged Patients With Gastric Cancer. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00253.	1.3	6
38	Construction and Analysis of the Tumor-Specific mRNA-miRNA-lncRNA Network in Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 1112.	1.6	33
39	An integrated classifier improves prognostic accuracy in non-metastatic gastric cancer. <i>Oncolimmunology</i> , 2020, 9, 1792038.	2.1	10
40	Intratumoral and Peritumoral Radiomics of Contrast-Enhanced CT for Prediction of Disease-Free Survival and Chemotherapy Response in Stage II/III Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 552270.	1.3	21
41	Intratumoral CD103 <sup>+</sup> CD4 <sup>+</sup> T cell infiltration defines immunoevasive contexture and poor clinical outcomes in gastric cancer patients. <i>Oncolimmunology</i> , 2020, 9, 1844402.	2.1	14
42	Targeting Wnt Signaling for the Treatment of Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3927.	1.8	46
43	Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles. <i>Cancer Medicine</i> , 2020, 9, 3043-3056.	1.3	4
44	Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103 <sup>+</sup> CD8 <sup>+</sup> T cells conferring favourable prognosis. <i>British Journal of Cancer</i> , 2020, 122, 1525-1534.	2.9	34
45	&lt;p&gt;The Anti-Tumor Effect of Nab-Paclitaxel Proven by Patient-Derived Organoids&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6017-6025.	1.0	9
46	Multimodality treatment for localized gastric cancer: state of the art and new insights. <i>Current Opinion in Oncology</i> , 2020, 32, 347-355.	1.1	19
47	Emerging precision therapies for gastric cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 299-311.	0.4	1
48	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020, 25, e460-e468.	1.9	29
49	Overexpressed MAGP1 Is Associated With a Poor Prognosis and Promotes Cell Migration and Invasion in Gastric Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1544.	1.3	6
50	Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer. <i>Annals of Oncology</i> , 2020, 31, 760-768.	0.6	101
51	Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model. <i>BMC Cancer</i> , 2020, 20, 314.	1.1	74
52	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 471-480.	3.0	17
53	Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit. <i>Cancer Medicine</i> , 2021, 10, 34-44.	1.3	12
54	SFRP4 drives invasion in gastric cancer and is an early predictor of recurrence. <i>Gastric Cancer</i> , 2021, 24, 589-601.	2.7	12

#	ARTICLE	IF	CITATIONS
55	Proteomic Workflows for High-Quality Quantitative Proteome and Post-Translational Modification Analysis of Clinically Relevant Samples from Formalin-Fixed Paraffin-Embedded Archives. <i>Journal of Proteome Research</i> , 2021, 20, 1027-1039.	1.8	20
56	<scp>Lymphocyteâ€activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epsteinâ€Barr virusâ€positive and MLH1â€defective gastric cancer patients</scp>. <i>International Journal of Cancer</i> , 2021, 148, 759-768.	2.3	15
57	Proteomic Profiling of Gastric Signet Ring Cell Carcinoma Tissues Reveals Characteristic Changes of the Complement Cascade Pathway. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100068.	2.5	4
58	An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 148-161.	1.3	14
59	A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection. <i>Frontiers in Oncology</i> , 2020, 10, 526746.	1.3	3
60	Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 162-172.	1.2	21
61	Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 655-665.	2.7	6
62	Computational Image Analysis Identifies Histopathological Image Features Associated With Somatic Mutations and Patient Survival in Gastric Adenocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 623382.	1.3	4
63	Prognostic Value of Postoperative Neutrophil and Albumin: Reassessment One Month After Gastric Cancer Surgery. <i>Frontiers in Oncology</i> , 2021, 11, 633924.	1.3	7
64	Characterization and clinical evaluation of microsatellite instability and loss of heterozygosity in tumorâ€related genes in gastric cancer. <i>Oncology Letters</i> , 2021, 21, 430.	0.8	2
65	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1429-1441.	0.9	2
66	A Fifteenâ€Gene Classifier to Predict Neoadjuvant Chemotherapy Responses in Patients with Stage IB to IIB Squamous Cervical Cancer. <i>Advanced Science</i> , 2021, 8, 2001978.	5.6	11
67	Pan-Cancer Analysis Reveals Distinct Metabolic Reprogramming in Different Epithelialâ€Mesenchymal Transition Activity States. <i>Cancers</i> , 2021, 13, 1778.	1.7	10
68	Dual effects of targeting S100A11 on suppressing cellular metastatic properties and sensitizing drug response in gastric cancer. <i>Cancer Cell International</i> , 2021, 21, 243.	1.8	12
69	Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. <i>Gut</i> , 2022, 71, 676-685.	6.1	21
70	Unsupervised Hierarchical Clustering Identifies Immune Gene Subtypes in Gastric Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 692454.	1.6	11
71	Tremellumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	1.7	31
72	Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e371-e382.	5.9	29

#	ARTICLE	IF	CITATIONS
73	Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6784.	1.8	5
74	Tryptophan potentiates CD8 <sup>+</sup> T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. , 2021, 9, e002840.		24
75	Proteomics provides individualized options of precision medicine for patients with gastric cancer. <i>Science China Life Sciences</i> , 2021, 64, 1199-1211.	2.3	8
76	lncRNAs as Hallmarks for Individualized Treatment of Gastric Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, .	0.9	1
77	Combining gene expression signature with clinical features for survival stratification of gastric cancer. <i>Genomics</i> , 2021, 113, 2683-2694.	1.3	7
78	Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts. <i>Nature Communications</i> , 2021, 12, 4840.	5.8	27
79	Microsatellite Instability and Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer: A Multicohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 8908-8915.	0.7	4
80	Alternative lengthening of telomeres is mechanistically linked to potential therapeutic vulnerability in the stemâ€like subtype of gastric cancer. <i>Clinical and Translational Medicine</i> , 2021, 11, e561.	1.7	6
81	CDX-1/CDX-2 Expression Is a Favorable Prognostic Factor in Epstein-Barr Virus-Negative, Mismatch Repair-Proficient Advanced Gastric Cancers. <i>Gut and Liver</i> , 2021, 15, 694-704.	1.4	0
82	Extracellular Matrix Characterization in Gastric Cancer Helps to Predict Prognosis and Chemotherapy Response. <i>Frontiers in Oncology</i> , 2021, 11, 753330.	1.3	11
83	Exploration of Lipid Metabolism in Gastric Cancer: A Novel Prognostic Genes Expression Profile. <i>Frontiers in Oncology</i> , 2021, 11, 712746.	1.3	13
84	Pelvic Ewing sarcoma: Should all patients receive pre-operative radiotherapy, or should it be delivered selectively?. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2618-2626.	0.5	4
85	Nanoparticle mediated codelivery of nifuratel and doxorubicin for synergistic anticancer therapy through STAT3 inhibition. <i>Colloids and Surfaces B: Biointerfaces</i> , 2020, 193, 111109.	2.5	18
86	Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit. <i>JCI Insight</i> , 2020, 5, .	2.3	50
87	A Multi-cohort Study of the Prognostic Significance of Microsatellite Instability or Mismatch Repair Status after Recurrence of Resectable Gastric Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 1153-1161.	1.3	9
88	Prognostic significance of perioperative tumor marker levels in stage II/III gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 17-27.	0.8	22
89	Clinical Implications of Microsatellite Instability in Early Gastric Cancer. <i>Journal of Gastric Cancer</i> , 2019, 19, 427.	0.9	15
90	Mapping the genomic diaspora of gastric cancer. <i>Nature Reviews Cancer</i> , 2022, 22, 71-84.	12.8	72

#	ARTICLE	IF	CITATIONS
91	Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	3
92	Application of an artificial neural network for predicting the potential chemotherapy benefit of patients with gastric cancer after radical surgery. <i>Surgery</i> , 2021, , .	1.0	3
93	Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy. <i>Journal of Breast Cancer</i> , 2020, 23, 599.	0.8	3
94	PRDX4 overexpression is associated with poor prognosis in gastric cancer. <i>Oncology Letters</i> , 2020, 19, 3522-3530.	0.8	2
95	Immunogenomic Landscape and Immune-Related Gene-Based Prognostic Signature in Asian Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 750768.	1.3	6
96	Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 2324-2331.	0.7	14
97	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. <i>Cancers</i> , 2021, 13, 5660.	1.7	16
98	Molecular subclassification of gastrointestinal cancers based on cancer stem cell traits. <i>Experimental Hematology and Oncology</i> , 2021, 10, 53.	2.0	5
99	Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 583-591.	0.7	2
100	A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology. <i>Molecular Cancer</i> , 2022, 21, 9.	7.9	2
101	Machine Learning-Based Model for the Prognosis of Postoperative Gastric Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 135-155.	0.9	15
102	Gastric cancer: An epigenetic view. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 90-109.	0.8	9
103	Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. <i>Nature Communications</i> , 2022, 13, 774.	5.8	52
104	An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy. <i>Journal of Translational Medicine</i> , 2022, 20, 100.	1.8	8
105	The Matrisome Is Associated with Metabolic Reprogramming in Stem-like Phenotypes of Gastric Cancer. <i>Cancers</i> , 2022, 14, 1438.	1.7	8
106	OSGc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 856988.	1.3	2
107	Intercellular communications and metabolic reprogramming as new predictive markers for immunotherapy responses in gastric cancer. <i>Cancer Communications</i> , 2022, 42, 572-575.	3.7	7
118	Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma. <i>Gastric Cancer</i> , 2022, 25, 697-711.	2.7	7

#	ARTICLE	IF	CITATIONS
119	Deep Learning-Based Protein Features Predict Overall Survival and Chemotherapy Benefit in Gastric Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
120	Gastric cancer biomarker analysis in patients treated with different adjuvant chemotherapy regimens within SAMIT, a phase III randomized controlled trial. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
121	SFRP4 and CDX1 Are Predictive Genes for Extragastric Recurrence of Early Gastric Cancer after Curative Resection. <i>Journal of Clinical Medicine</i> , 2022, 11, 3072.	1.0	1
122	The EEF1AKMT3/MAP2K7/TP53 axis suppresses tumor invasiveness and metastasis in gastric cancer. <i>Cancer Letters</i> , 2022, 544, 215803.	3.2	14
123	Synaptotagmin 11 scaffolds MKK7â€™JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	7
124	Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer. <i>Cancers</i> , 2022, 14, 3191.	1.7	8
125	Prognosisâ€™related gene signature is enriched in cancerâ€™associated fibroblasts in the stemâ€™like subtype of gastric cancer. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	3
127	Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 3940.	1.7	5
128	The pathophysiological role of aminoacyl-tRNA synthetases in digestive system diseases. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	4
129	Single Cell Analysis Reveals Reciprocal Tumor-Macrophage Intercellular Communications Related with Metabolic Reprogramming in Stem-like Gastric Cancer. <i>Cells</i> , 2022, 11, 2373.	1.8	3
130	Deep learning predicts resistance to neoadjuvant chemotherapy for locally advanced gastric cancer: a multicenter study. <i>Gastric Cancer</i> , 2022, 25, 1050-1059.	2.7	4
131	Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1247-1268.	1.3	19
132	Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGAST. <i>Journal of Clinical Medicine</i> , 2022, 11, 5439.	1.0	0
133	An artificial intelligence model to predict survival and chemotherapy benefits for gastric cancer patients after gastrectomy development and validation in international multicenter cohorts. <i>International Journal of Surgery</i> , 2022, 105, 106889.	1.1	5
134	Identification of a Biomarker Combination for Survival Stratification in pStage II/III Gastric Cancer after Curative Resection. <i>Cancers</i> , 2022, 14, 4427.	1.7	2
135	Single Cell Analysis of Gastric Cancer Reveals Non-Defined Telomere Maintenance Mechanism. <i>Cells</i> , 2022, 11, 3342.	1.8	3
136	DKK1 as a robust predictor for adjuvant platinum chemotherapy benefit in resectable pStage II-III gastric cancer. <i>Translational Oncology</i> , 2023, 27, 101577.	1.7	0
137	Prognostic and predictive value of a pathomics signature in gastric cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	31



#	ARTICLE	IF	CITATIONS
138	Clinical Significance of <i>SEC11A</i> Expression in Patients With Locally Advanced Gastric Cancer. <i>Anticancer Research</i> , 2022, 42, 5885-5890.	0.5	0
139	Selective cytotoxicity of a novel mitochondrial complex I inhibitor, YK-135, against EMT-subtype gastric cancer cell lines due to impaired glycolytic capacity. <i>BMB Reports</i> , 2022, 55, 645-650.	1.1	0
140	Editorial: Clinicopathological factors and staging in gastrointestinal cancers. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
141	Preoperative 18F-FDG PET/CT radiomics analysis for predicting HER2 expression and prognosis in gastric cancer. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, 13, 1537-1549.	1.1	4
142	Tumour infiltrating lymphocytes and survival after adjuvant chemotherapy in patients with gastric cancer: post-hoc analysis of the CLASSIC trial. <i>British Journal of Cancer</i> , 2023, 128, 2318-2325.	2.9	2
143	Gastric Cancer Epidemiology, Genetics, and Screening. , 2023, , 451-459.		0
147	Early stage gastric adenocarcinoma: clinical and molecular landscapes. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 453-469.	12.5	7
166	Translating Molecular Subtypes into Clinical Practice: Precision Medicine in Gastric Cancer. , 0, , .		0